Boost Plus

DIETARY_SUPPLEMENT4 trials

Sponsors

Bristol-Myers Squibb, Case Comprehensive Cancer Center, Columbia University

Conditions

Healthy SubjectsHyperinsulinemiaInsulin ResistanceMalignant NeoplasmNon-Alcoholic Fatty Liver DiseaseObesityOverweight and ObesityPrediabetic State

Phase 1

Phase 1 Oral Solution and Crushed Tablet Relative Bioavailability Study of Apixaban When Administered Through a Nasogastric Tube in Healthy Subjects

CompletedNCT02034591

Bristol-Myers SquibbHealthy Subjects

Start: 2011-10-31End: 2011-11-30Updated: 2016-06-23

Pancreatic Clamp in NAFLD

CompletedNCT05724134

Columbia UniversityHyperinsulinemia, Insulin Resistance, Non-Alcoholic Fatty Liver Disease +2

Start: 2023-08-29End: 2025-09-24Updated: 2026-01-12

Dexamethasone/Pancreatic Clamp P&F

WithdrawnNCT06126354

Columbia UniversityInsulin Resistance, Non-Alcoholic Fatty Liver Disease, Overweight and Obesity +1

Start: 2024-07-01End: 2026-03-31Updated: 2024-07-10

Unknown Phase

Early Oral Supplementation in Improving Nutritional Status in Patients Undergoing Hematopoietic Stem Cell Transplant

TerminatedNCT02590107

Case Comprehensive Cancer CenterMalignant Neoplasm

Start: 2016-04-01End: 2018-03-01Updated: 2018-05-15

Related Papers

Relative Bioavailability of Apixaban Solution or Crushed Tablet Formulations Administered by Mouth or Nasogastric Tube in Healthy Subjects

Clinical Therapeutics2015-07-1639 citations